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a b s t r a c t
To subvert host antiviral immune responses, many viruses have evolved countermeasures to inhibit IFN
signaling pathway. Porcine bocavirus (PBoV), a newly identiﬁed porcine parvovirus, has received
attention because it shows clinically high co-infection prevalence with other pathogens in post-
weaning multisystemic wasting syndrome (PWMS) and diarrheic piglets. In this study, we screened
the structural and non-structural proteins encoded by PBoV and found that the non-structural protein
NP1 signiﬁcantly suppressed IFN-stimulated response element (ISRE) activity and subsequent IFN-
stimulated gene (ISG) expression. However, NP1 affected neither the activation and translocation of
STAT1/STAT2, nor the formation of the heterotrimeric transcription factor complex ISGF3 (STAT1/STAT2/
IRF9). Detailed analysis demonstrated that PBoV NP1 blocked the ISGF3 DNA-binding activity by
combining with the DNA-binding domain (DBD) of IRF9. In summary, these results indicate that PBoV
NP1 interferes with type I IFN signaling pathway by blocking DNA binding of ISGF3 to attenuate innate
immune responses.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Innate immunity is the ﬁrst line of host defense against invading
pathogens. Type I interferons (IFNs), including IFN-α and IFN-β,
represents the principal response of the innate immune system to
virus invasion (Gonzalez-Navajas et al., 2012). During viral infection,
host pattern recognition receptors (PRRs) recognize viral compo-
nents or replication intermediates, known as pathogen-associated
molecular patterns (PAMPs), and trigger signals that result in the
expression of type I IFNs (Rathinam and Fitzgerald, 2011). Following
binding of the IFN receptor complex, the synthesis and secretion of
IFN-α/β initiates signaling through the Janus kinases/signal trans-
ducers and activators of transcription (JAK/STAT) pathway
(O'Sullivan et al., 2007), resulting in the phosphorylation of STATs
(Leonard and O'Shea, 1998; Pellegrini and Dusanter-Fourt, 1997).
The phosphorylated STATs interact with the transcription factor
IRF9 to form the heterotrimeric transcription factor complex, IFN-
stimulated gene factor 3 (ISGF3). This complex translocates to the
nucleus where it binds speciﬁc regulatory DNA sequences called
IFN-stimulated response elements (ISREs) via IRF9 (Qureshi et al.,
1995; Veals et al., 1993). This binding step drives the transcription of
many IFN-stimulated genes (ISGs) involved in antiviral states, such
as double-stranded RNA-dependent protein kinase R (PKR), 20,50-
oligoadenylate synthetase (OAS), myxovirus resistance 1 (Mx1),
ISG15, ISG56 and ISG56 (Borden et al., 2007; Fu et al., 1990).
To combat the antiviral effects of IFN response, viruses usually
develop various strategies to disrupt the type I IFN system mainly
by interfering with IFN induction and inhibiting IFN signaling. For
example, at least eight proteins encoded by Severe acute respiratory
syndrome coronavirus (SARS-CoV) and three IRF homolog proteins
encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) func-
tion as antagonists of IFN production (Totura and Baric, 2012);
Several viral proteins, such as porcine reproductive and respiratory
syndrome virus (PRRSV) NSP1β protein (Wang et al., 2013), foot-
and-mouth disease virus (FMDV) 3C protein (Du et al., 2014) and
Hepatitis C virus (HCV) NS5A (Bobardt et al., 2013), counteract host
antiviral responses by interfering with IFN signaling.
Porcine Bocavirus (PBoV), a newly emergent parvovirus belonging
to the genus bocavirus of the parvovirinae subfamily, was ﬁrst
identiﬁed in Swedish pigs with post-weaning multisystemic wasting
syndrome (PMWS) (Allander et al., 2005; Blomstrom et al., 2009;
Chen et al., 1986; Manteufel and Truyen, 2008). To date, a number of
different strains of PBoV have been reported worldwide in PMWS,
respiratory, diarrheic or asymptomatic swine (Blomstrom et al., 2009;
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Huang et al., 2014; Zhai et al., 2010; Zhang et al., 2014, 2013). Although
the pathogenesis of PBoV infection remains to be clariﬁed, there is a
signiﬁcantly higher prevalence of co-infection with Porcine circovirus
type 2 (PCV2), PRRSV, Porcine torque teno virus (PTTV), and classical
Swine fever virus (CSFV) in PBoV-positive pigs, indicating that PBoV
plays a role in the co-infection process (Huang et al., 2014; Zhai et al.,
2010). Moreover, high prevalence of PBoV was detected in inguinal
lymph node and spleen tissues in PBoV-positive pigs (Liu et al., 2014).
Hence, it is speculated that PBoV is an immunosuppressive pathogen
(Zhou et al., 2014). The full-length genome sequence of PBoV exceeds
5 kb and contains three potential open reading frames (ORFs) encod-
ing two non-structural proteins (NS1 and NP1) and two structural
proteins (VP1 and VP2). The genome organization is very similar to
that of other bocavirus (Chen et al., 2010; Qiu et al., 2007). Despite
extensive efforts, isolation of PBoV and the generation of an infectious
clone have not yet been successful. To explore the possible mechanism
(s) underlying the immunosuppressive effects of PBoV, we have
focused on the effects of PBoV-encoded proteins on innate immunity.
Recent study demonstrated that human bocavirus (HBoV) NP1
inhibits both Sendai virus- and poly(dA-dT)-induced IFN-β production
(Zhang et al., 2012). We also found that PBoV NP1 could inhibit Sendai
virus-induced IFN-β production (unpublished data). In this study, we
demonstrated that, in addition to inhibiting IFN-β production, PBoV
NP1 also antagonize IFN signaling by reducing the DNA-binding
activity of ISGF3, exhibiting a broad-spectrum ability to inhibit innate
immune responses.
Results
NP1 interferes with the IFN α/β signaling pathway
It is well-known that IFN-α/β initiates a series of signaling
cascades through the JAK/STAT pathway, resulting in the expression
of a set of ISGs, which collaboratively suppress the replication of
viruses and contribute to the development of adaptive immune
responses (Platanias, 2005). PBoV encodes two structural proteins
(VP1, VP2) and two non-structural proteins (NS1, NP1). To identify
whether these proteins inﬂuences type I IFN signaling, we exam-
ined the effects of PBoV encoding proteins expression on ISG
promoter activity in response to IFN-α/β stimulation. To this end,
HEK-293 cells were co-transfected with ISRE-Luc (containing a
consensus sequence for the IFN-stimulated response element (ISRE)
of the ISG promoter), pRL-TK (internal control plasmid) and the
different PBoV protein expression vectors (VP1, VP2, NS1, NP1).
Empty expression vectors were used as controls. At 24-h post-
transfection, the cells were treated with IFN-α or IFN-β, ISRE-Luc
was measured in whole-cell extracts using a dual luciferase reporter
assay at 6 h after this treatment. As shown in Fig. 1A and B, the
activation of ISRE promoter was markedly induced by IFN-α/β
stimulation, while this induction was strongly impaired by NP1
(Fig. 1A and B). Conversely, overexpression of VP1 and VP2
enhanced the IFN-α/β-induced ISRE activation. Using real-time
RT-PCR, we also analyzed the expression of several ISGs at the
mRNA level in cells overexpressing NP1. As expected, ectopic
expression of NP1 signiﬁcantly reduced the expression of ISG15,
ISG54 and ISG56 mRNA induced by IFN-α (Fig. 1C). These data
indicated that PBoV NP1 functions as an antagonist of IFN signaling.
NP1 does not prevent STAT1/STAT2 phosphorylation and nuclear
translocation
In response to type I IFN, the transcription factors STAT1 and STAT2
are phosphorylated at tyrosine residues by JAK1 and tyrosine kinase 2
(JAK1/Tyk2) and translocated to the nucleus (Darnell et al., 1994).
Therefore, we investigated whether NP1 inhibits the phosphorylation
of STAT1 or STAT2. To this end, HEK-293T cells were transfected with
pCAGGS-HA-NP1 and then incubated with IFN-α. The results showed
that phosphorylation of STAT1 (P-Y701-STAT1) and STAT2 (P-Y690-
STAT2) were obviously induced by IFN-α in cells with or without NP1
expression (Fig. 2A). Similarly, the endogenous expression of STAT1,
STAT2 and IRF9 was also maintained at a steady-state level in the
presence or absence of NP1 (Fig. 2A). These observations indicated that
NP1 did not prevent STATs phosphorylation or induce the degradation
of STATs and IRF9.
In addition to targeting STATs to reduce phosphorylation or
stimulate degradation, some viruses subvert the IFN signaling
pathway by modulating nuclear translocation of STATs (Palosaari
et al., 2003; Reid et al., 2006). Consequently, we next examined the
effects of NP1 on IFN-α-stimulated translocation of STAT1 or
STAT2. To this end, HeLa cells were transfected with a HA-tagged
NP1 construct or empty vector. At 24-h post-transfection, cells
were treated with IFN-α for 20 min. As shown in Fig. 2B, treatment
with IFN-α rapidly stimulated nuclear translocation of both STAT1
and STAT2, and this translocation was not affected in cells over-
expressing NP1, demonstrating that NP1 has no effect on IFN-α-
induced nuclear translocation of STAT1/2. Furthermore, similar to
Bovine parvovirus (BPV), minute virus of canines (MVC), and HBoV
(Chen et al., 2010; Lederman et al., 1984; Sukhu et al., 2013), PBoV
NP1 was localized in the nucleus (Fig. 2B).
NP1 does not impair ISGF3 complex formation but inhibits its DNA-
binding activity
In the phosphorylated form, STATs bind to IRF9 to form a
complex IFN-stimulated gene factor 3 (ISGF3) (Schindler et al.,
1992), which acts as a transcription factor within ISRE sites in the
promoter or enhancer regions of type I IFN responsive genes
(Darnell et al., 1994). By using a reporter assay, we found that
the IRF9 expression up-regulated ISRE activity and NP1 suppressed
IRF9-induced ISRE activation. However, possibly due to a lack of
the active form, non-phosphorylated STAT1 or STAT2 expression
did not have any effect on ISRE activity (data not shown),
indicating that NP1 targets at or downstream of the ISGF3
complex. It is known that essential contacts between IRF9 and
STAT1 are required for ISGF3 stability and transcriptional activity
(Horvath et al., 1996). As previously described, the human herpes-
virus 6B (HHV-6B) IE1 protein disrupted ISGF3 complex formation
and inhibited its binding to the ISRE by binding STAT2 within the
111–397 region (Jaworska et al., 2010). To address this issue, we
used CoIP assays to determine whether NP1 alters ISGF3 complex
formation. Constructs encoding Flag-tagged STAT1, STAT2, IRF9, or
empty vector plasmid were co-transfected into HEK-293T cells
with HA-tagged NP1 or empty vector. The transfected cells were
stimulated with IFN-α for 6 h before lysates were prepared for
immunoprecipitation with an anti-IRF9 antibody. As shown in
Fig. 3A, Flag-IRF9 co-precipitated with Flag-STAT1 and Flag-STAT2,
demonstrating that the Flag-tagged protein formed an ISGF3
complex after IFN treatment. This co-precipitation was not
impaired by NP1 expression (Fig. 3A). Interestingly, the HA-
tagged NP1 and ISGF3 complex were immunoprecipitated with
the anti-IRF9 antibody (Fig. 3A), suggesting that NP1 interacts with
the ISGF3 complex but does not impair its formation.
Active ISGF3 was identiﬁed as an ISRE-binding factor present in
extracts from IFN-α-treatment (Stark and Kerr, 1992). Due to the
same cellular localization, we speculated that NP1 inhibits the
transcription factor function of ISGF3. Therefore, we examined
whether NP1 inhibits the DNA-binding activity of ISGF3. HEK-293T
cells were transfected with HA-tagged NP1 or empty vector. After
transfection, the cells were treated with IFN-α for 6 h and ChIP
assays were performed. Our results showed that NP1 inhibited the
IFN-induced binding of ISGF3 to the ISG56 promoter (Fig. 3B). In
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contrast, the DNA-binding activity of a positive control, trimethyl-
histone H3 was not affected by NP1 (Fig. 3B), indicating that NP1
blocks the binding activity of ISGF3 to the ISG56 promoter. Taken
together, these observations indicated that NP1 inhibits IFN
signaling by impairing ISGF3 DNA-binding activity.
NP1 interacts with the IRF9 DNA-binding domain
The DNA-binding components of ISGF3 provide the speciﬁcity for
binding to the promoter in an association that is mediated by IRF9
and STAT1. However, IRF9 is required to provide the main contact
with the core of the ISRE consensus sequence, while STAT1 has only
limited DNA-binding afﬁnity (Darnell et al., 1994; Veals et al., 1993).
Because there is an obvious interaction between NP1 and ISGF3, it is
possible that NP1 inhibits the DNA-binding step of ISGF3 by interact-
ing with IRF9. To test this hypothesis, HEK-293T cells were transfected
with HA-tagged NP1 and Flag-tagged IRF9 and then treated or mock
treated with IFN-α for 6 h. Co-IP assays were performed to determine
the interaction between NP1 and IRF9. As shown in Fig. 4A, co-
immunoprecipitation of IRF9 and NP1 was observed in assays using
both anti-Flag tag and anti-HA antibodies (middle and lower panels),
thus conﬁrming the interaction between NP1 and IRF9.
IRF9, as a member of the IRF family, contains two major
domains, an N-terminal DNA-binding domain (DBD) and a C-
terminal domain, which are largely responsible for its interactions.
The DNA-binding region for the ISRE have been identiﬁed in the
well-conserved DBD (Yanai et al., 2012). As mentioned above, the
PBoV NP1 protein binds IRF9 and blocks the binding of IRF9 to
responsive DNA sequences within the promoter (Fig. 3A and
Fig. 4A). These observations indicated that this inhibition may
involve in the IRF9 DBD. To conﬁrm this speculation, we investi-
gated the capacity of NP1 to interact with the IRF9 DBD. The N-
terminal mutant containing the DBD region (IRF9-1-199) was
constructed and the results of Co-IP assay showed that NP1 bound
to the IRF9 DBD (Fig. 4B).
The DBD contains a signature repeat of tryptophan residues
within a unique helix-turn-helix structure which is responsible
for DNA-binding activity (Escalante et al., 2007; Fujii et al.,
1999). Knowing the structure loop 1 (L1) and α-helix 3 (α3) of
the IRFs DBD play important role in DNA binding, it is possible
that PBoV NP1 blocks this binding surface to inhibit IRF9
binding activity. Although the crystal structure of the IRF9/
DNA complex has not yet been resolved, a Histidine (H) residue
on L1 and a Arginine (R) residue on α3 are completely conserved
in the IRF family, and which were identiﬁed as an important
DNA recognition sites in IRF2, IRF3 and IRF7 (Escalante et al.,
2007; Fujii et al., 1999). Thus, we speculated that H44 on L1 and
R85 on α3 of IRF9 perform binding function in IRF9/DNA-
association. To investigate whether the binding surface of IRF9
is required for interaction with NP1, we used two constructs by
incorporating mutations in Loop1 or α-helix 3 of the IRF9 DBD
in Co-IP assays (Fig. 4C). As shown in Fig. 4D, compared with the
wild-type controls, less NP1 was co-immunoprecipitated with
IRF9-1-199-H44A, suggesting that the conserved Histidine
Fig. 1. PBoV NP1 interferes with IFN α/β signaling pathway. (A and B) Overexpression of NP1 inhibited type I IFN-induced ISRE promoter activation. HEK-293T cells were co-
transfected with ISRE-Luc, pRL-TK, and HA-tagged NS1, NP1, VP1 or VP2 expression plasmids. Twenty-four hours after the initial transfection, the cells were treated with IFN-
α or IFN-β. Dual luciferase assays were performed after treatment. The resultant ratios were normalized to fold change values with reference to the untreated empty vector
control. The results represent the means and standard deviations of data from three independent experiments. (C) Overexpression of NP1 inhibited IFN-α induced
transcription of ISG15, ISG54 and ISG56. HEK-293T cells grown in 24-well plates were transfected with 1 μg of a plasmid encoding PBoV NP1 protein (pCAGGS-HA-NP1) or an
empty vector. At 24-h post-transfection, the cells were treated with IFN-α and the cells were collected after a further 6 h. Total RNA was extracted from the cells, and the
expression levels of the ISG15, ISG54 and ISG56, and GAPDH genes were evaluated by quantitative real-time RT-PCR. The results are expressed as increases in mRNA levels
relative to those in transfected cells without IFN infection and were normalized to the expression level of the GAPDH housekeeping gene. One of three experiments is shown.
*Po0.05, **Po0.01, Student's t-test.
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residue contributes to NP1 binding. However, similar amounts
of NP1 were immunoprecipitated with IRF9-1-199-R85A and the
wild-type IRF9-1-199 control (Fig. 4D), possibly because Argi-
nine 85 of IRF9 is not required for DNA binding. Taken together,
these data further demonstrate a mechanism by which PBoV
NP1 disrupts the IFN signaling pathway by interaction with the
DNA-binding domain of IRF9.
Discussion
In this study, we demonstrated that PBoV NP1 antagonizes the
antiviral innate immune by interfering with type I IFN signaling.
Our data also revealed that PBoV NP1 interacts with the DBD of
Fig. 2. PBoV NP1 does not degrade or prevent phosphorylation and nuclear translocation
of STAT1/STAT2. (A) Effects of NP1 on STAT1/2 phosphorylation and expression. HEK-293T
cells were mock-transfected or transfected with HA-tagged NP1 expression plasmid. At
24-h post-transfection, the cells were treated with IFN-α (1000 IU/ml) for 30min. Cell
lysates were collected for immunoblot analysis with antibodies directed against phos-
phorylated STAT1 (Y701), phosphorylated STAT2 (Y690), STAT1, STAT2, IRF9, HA, or β-actin.
(B) NP1 did not prevent STAT1 or STAT2 translocation. HeLa cells were transfected with
HA-tagged NP1 expression plasmid. At 24-h post-transfection, the cells were treated with
IFN-α (1000 IU/ml) for 30min. Cells were ﬁxed and stained with mouse anti-HA speciﬁc
for NP1 (green) and rabbit antibody for STAT1 or STAT2 (red). Cells were viewed under the
confocal microscope (Olympus Fluoview ver. 3.1). One of three experiments is shown.
Fig. 3. PBoV NP1 does not impair ISGF3 complex formation but inhibits its DNA-
binding activity. (A) NP1 did not affect formation of the ISGF3 complex. 293T cells
were transfected with FLAG-IRF9, FLAG-STAT1, FLAG-STAT2 or empty vector
plasmid and HA-tagged NP1 or empty vector plasmid. At 24-h post-transfection,
the cells were incubated with IFN-α for 6 h. Cells were lysed and subjected to
immunoprecipitation (IP) using rabbit anti-IRF9 antibody. The whole-cell lysates
and immunoprecipitation complexes were analyzed by immunoblotting using
mouse anti-Flag or mouse anti-HA antibodies. (B) ChIP analysis of ISGF3 binding
to the IFN-β promoter. HEK-293T cells were transfected with NP1 or empty
expression vector (10 μg each). At 24 h post-transfection, the cells were incubated
with IFN-α for 6 h. Cells were lysed and subjected to immunoprecipitation (IP)
using rabbit anti-IRF9 antibody. ChIP assays were then performed as described in
the Materials and methods section. Real-time PCR analysis of the relative binding of
ISGF3 to the ISG56 promoter was performed. The results were expressed as a signal
ratio, which represents the signal to the background (IgG) ratio. One of three
experiments is shown.
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IRF9, and blocks the DNA-binding activity of ISGF3, thus impeding
ISG expression (Fig. 5).
Members in the Parvoviridae family infect a wide range of
hosts, and their evasion of the innate immune system has rarely
been reported. Infection with the minute virus of mice (MVM)
inhibited poly(I:C)-induced IL-6 expression in mouse embryonic
ﬁbroblasts (Mattei et al., 2013) and porcine parvovirus (PPV)
infection blocked IFN-β production by NS2 inhibition of poly(I:
C)-induced IFN-β promoter activation (Lin et al., 2013). Previous
studies have demonstrated the HBoV NS1 and NP1 proteins block
SeV- and poly(dA-dT)-induced IFN-β production (Zhang et al.,
2012), and the structural protein VP2 up-regulated IFN-β produc-
tion (Luo et al., 2013). To determine whether bocavirus could
antagonize the IFN signaling pathway, we screened the effects of
PBoV encoding proteins on IFN signaling in present study. We
found PBoV structural proteins, VP1 and VP2, further enhanced
IFN-induced ISRE activation, while non-structural protein NP1
inhibited transcript levels of ISGs and ISRE promoter activity. In
addition, our experiments demonstrated PBoV NS1 and NP1 both
inhibits type I IFN production (data not shown). These results
Fig. 4. PBoV NP1 interacts with the IRF9 DNA-binding domain. (A) PBoV NP1 protein interacts with IRF9. HEK-293T cells were transfected with expression constructs
encoding HA-tagged NP1 protein and Flag-tagged IRF9. At 24 h post-transfection, the cells were treated or mock-treated with IFN-α for 6 h. Cells were then lysed and
subjected to immunoprecipitation (IP) using mouse anti-FLAG tag or mouse anti-HA tag antibodies. The whole-cell lysates and immunoprecipitation (IP) complexes were
analyzed by immunoblotting (IB) using rabbit anti-Flag or mouse anti-HA antibodies. (B) PBoV NP1 protein interacts with IRF9 DNA binding domain. HEK-293T cells were
transfected with HA-tagged NP1 expression constructs and Flag-tagged IRF9-1-199 deletion mutants for 24 h. Cell lysates were immunoprecipitated using mouse anti-Flag
tag. The whole-cell lysates and immunoprecipitation (IP) complexes were analyzed by immunoblotting (IB) using mouse anti-Flag or mouse anti-HA. (C) Schematic
representation of the N-terminal domain of IRF9 and their derivatives (IRF9-1-199-H44A and IRF9-1-199-R85A). (D) Co-IP analysis of the associations of the N-terminal
mutants of IRF9 with NP1. HA-tagged NP1 expression constructs were co-transfected with Flag-tagged IRF9-1-199-H44A or Flag-tagged IRF9-1-199-R85A mutants in HEK-
293T cells for 24 h. Cell lysates were immunoprecipitated using mouse anti-FLAG tag antibody. The whole-cell lysates and immunoprecipitation (IP) complexes were
analyzed by immunoblotting (IB) using mouse anti-Flag or mouse anti-HA antibodies. One of three experiments is shown.
Fig. 5. The proposed model for association between PBoV NP1 and the IRF9 DNA-
binding domain. PBoV NP1 interacts with the DNA-binding domain of IRF9 to block
the DNA-binding step of ISGF3, resulting in reduction of ISG expression.
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indicate that non-structural proteins provide type I IFN resistance
against bocavirus infection, while structural proteins contribute to
host immune protection.
The type I IFN system provides a powerful antiviral response that
protects the host from virus infection. To subvert the antiviral effects
of IFN-induced ISGs, viruses were shown to express certain proteins
that negatively regulate type I IFN signaling by targeting the JAK-
STAT pathway at different levels, including impeding IFN receptor
activation (Bisson et al., 2009), degrading STATs (Tay et al., 2013;
Ulane and Horvath, 2002), inhibiting STATs phosphorylation
(Caignard et al., 2007; Devaux et al., 2007), blocking STAT1/STAT2
nuclear translocation (Chen et al., 2013; Xu et al., 2014), and
disturbing ISGF3 formation (Jaworska et al., 2010; Lin et al., 2006).
In this study, we screened the components of JAK-STAT pathway and
found that PBoV NP1 does not affect the amounts of STATs and IRF9
in IFN-α-treated cells, nor does it alter the IFN-induced phosphoryla-
tion of STAT1/STAT2. Furthermore, NP1 hardly affected the nuclear
translocation of STATs. Interestingly, we found NP1 interacted with
ISGF3 without any effect on its formation but inhibited ISGF3 DNA-
binding activity. Thus, we identiﬁed PBoV NP1 as an antagonist of the
type I IFN system to mediate negative regulation of IFN signaling by
targeting the DNA-binding step of ISGF3. Because we did not
investigate the potential interaction of NP1 with CREB-binding
protein (CBP) in the present study, we could not exclude the
possibility that NP1 may impair CBP function. Given that binding of
transcription factors to promoters and combining with CBP are two
independent events, we mainly focused on the mechanism by which
the DNA-binding of ISGF3 is inhibited.
Acting as key transcription factors in the IFN signaling pathway,
the activated ISGF3 recognize and bind directly to the conserved
DNA sequences in the nucleus. Multiple levels of regulation occur
during ISGF3 translocation to the nucleus. However, to the best of
our knowledge, only the rabies virus P protein has been shown to
inhibit ISGF3 binding to the ISRE directly, whereas it also blocks
STAT1 nuclear translocation (Vidy et al., 2007). It is unclear at
present how the PBoV NP1 protein inhibits the binding of ISGF3 to
the DNA. We speculate that there are two possibilities: 1) NP1
interacts directly with the IRF9 DBD to block the binding step;
2) NP1 interacts directly with the promoter to block the binding site
on ISRE. In this study, we conﬁrmed that NP1 interacts with IRF9
DBD. This result is consistent with a previous report (Zhang et al.,
2012), which described the interaction of the HBoV NP1 proteinwith
the IRF3 DBD. Furthermore, we noted that a potential DNA binding
site (H44) on Loop1 of IRF9 contributes to IRF9 and NP1 association,
indicating that NP1 acts as an obstruction on the DNA-binding
interface of IRF9, and in turn interferes with the IRF9 DNA-binding
activity. Considering the structural similarity among the different IRF
DBDs and the histidine residue on Loop1 is also highly conserved in
IRFs family, it is possible that NP1 interacts with similar binding sites
on the DBDs of other IRFs to mediate broad-spectrum impairment of
the IFN system. However, we cannot exclude the possibility that NP1
interacts directly with the responsive DNA-binding site of the
promoter. Indeed, as previously shown, the KSHV K-bZIP protein,
which is an IFN antagonist, interacts directly with the PRDIII-I region
of IFN-β and the ISRE region of RANTES (Lefort et al., 2007).
Considering that bocavirus NP1 has effects on RNA processing and
DNA replication (Sukhu et al., 2013; Sun et al., 2009) and the
existence of a potential nucleic acid recognition site at the N-
terminal region of PBoV NP1 (http:// http://smart.embl-heidelberg.
de/; http://pfam.xfam.org), it is possible that PBoV NP1 recognizes
and binds to the DNA sequence on the promoter.
Bocavirus NP1 contains a highly phosphorylated N-terminal
and a conserved C-terminal. Previous study demonstrated HBoV
and BPV NP1 are both able to recover MVC replicative form DNA as
same as MVC NP1, suggesting that functions of NP1 could be cross-
complemented among Bocavirus (Sun et al., 2009). In agreement,
HBoV NP1 interacts with IRF3 DBD (Zhang et al., 2012), while PBoV
NP1 interacted with the IRF9 DBD in current study. Therefore, it
can be speculated that a functionally conserved domain in NP1 is
responsible for its IRF DBD binding activity. Moreover, the same
localization of NP1 and activated ISGF3 in the nucleus lays the
foundation for their interaction, suggesting that the subcellular
location of NP1 may affect its function as an IFN antagonist.
Further studies are required to fully elucidate the function of
NP1 as an IFN antagonist.
Materials and methods
Cells and virus
HEK-293T cells and HeLa cells were maintained in RPMI 1640
(Life Technologies) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) at 37 1C in a humidiﬁed 5% CO2 incubator.
Plasmids
The luciferase reporter plasmid pISRE-Luc has been described
previously (Zhong et al., 2013). The internal control plasmid pRL-TK
was purchased from Promega. All primers used for the construction
of plasmids are listed in Table 1. To construct the expression plasmids
encoding individual PBoV proteins, DNA fragments encoding the full-
length NS1, NP1, VP1, VP2 proteins were ampliﬁed by PCR from the
almost full-length cDNA clone of bocavirus pig/SX/China/2010 (Gen-
Bank accession number HQ223038). The fragments were then sub-
cloned into the pCAGGS-HA vector. The full-length cDNA of IRF9
(GenBank accession number NM_006084) was ampliﬁed from total
RNA extracted from HEK-293T cells and cloned into the pCMV-Tag2B
expression vector to generate pCMV-IRF9. Truncation of IRF9 (IRF9-1-
199; residues 1–199) was constructed by PCR and cloned into the
pCMV-Tag2B expression vector. Constructs encoding mutants of IRF9-
1-199 (IRF9-1-199-H44A and IRF9-1-199-R85A) were generated by
overlapping extension PCR using speciﬁc mutagenic primers (avail-
able upon request). The expression plasmids Vim-ﬂag-STAT1 and
Vim-ﬂag-STAT2 were purchased from Vigene (China).
Transfection and luciferase reporter assay
HEK-293T cells and HeLa cells were transfected using Lipofecta-
mine 2000 reagent (Invitrogen), according to the manufacturer's
instructions. For luciferase reporter assays, HEK-293T cells in 24-
well plates were co-transfected with 0.1-μg/well reporter plasmid
ISRE-Luc with 0.05-μg/well internal control plasmid pRL-TK. At 24 h
after the initial co-transfection, the cells were further stimulated with
IFN-α ( Catalog no. 11101-2, PBL assay science) or IFN-β (Catalog no.
300-02BC, Peprotech) for 6 h. Luciferase activity was determined
using the Dual Luciferase Reporter Assay System (Promega), accord-
ing to the manufacturer's protocol. Data represent relative ﬁreﬂy
luciferase activity normalized to Renilla luciferase activity and are
representative of three independently conducted experiments.
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted from the cells with TRIzol reagent
(Invitrogen), and an aliquot (1 μg) was reverse transcribed to
cDNA by using avian myeloblastosis virus (AMV) reverse tran-
scriptase (Roche). To determine the effects of NP1 protein on the
expression of ISG15, ISG54 and ISG56, HEK-293T cells in 24-well
plates were transfected with 1 μg of the empty vector or a plasmid
encoding the NP1 protein. After 24 h, the cells were mock
stimulated or stimulated with IFN-α. The cDNA (1 μl of the 20-μl
RT reaction mixture) was then used as the template in a SYBR
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green PCR assay (Applied Biosystems). The abundance of the
individual mRNA transcripts in each sample was assayed three
times and normalized to that of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA (the internal control).
Co-immunoprecipitation and immunoblot assays
Brieﬂy, HEK-293T cells cultured in 60-mm dishes were trans-
fected with the appropriate plasmids. After 28 h, the cells were
harvested by the addition of 150-μl lysis buffer (4% SDS, 3%
dithiothreitol [DTT], 0.065 mM Tris–HCl [pH 6.8], 30% glycerin),
and the protein concentrations in the whole-cell extracts were
measured. Equal amounts of samples were then subjected to SDS-
PAGE and analyzed for the expression of STAT1, p-STAT1, STAT2, p-
STAT2 and IRF9 proteins by immunoblotting using the following
antibodies (raised in rabbit): anti-STAT1, anti-p-STAT1 (both Santa
Cruz), anti-STAT2, anti-p-STAT2 (both ABclone), and anti-IRF9
antibody (Santa Cruz), respectively. An anti-hemagglutinin (HA)
antibody (MBL) was used for immunoblotting to conﬁrm the
expression levels of HA-tagged PBoV NP1 protein. The expression
of β-actin was detected with a mouse anti-β-actin monoclonal
antibody (MBL) to demonstrate equal protein sample loading.
For co-immunoprecipitation experiments, HEK-293T cells in
100-mm dishes were transiently transfected with the indicated
plasmids using Lipofectamine 2000 according to the manufac-
turer's instructions (Invitrogen). Transfected HEK-293T cells from
each dish were washed with phosphate-buffered saline (PBS) and
lysed for 20 min at 4 1C in 1-ml lysis buffer (50 mM Tris–HCl [pH
7.5], 150 mM NaCl, 1% NP-40, 20 nM phenylmethylsulfonyl ﬂuoride
[PMSF]), and the protein concentration was measured and
adjusted. For each immunoprecipitation, 500 μg of cell lysate
protein was incubated with 2-μg mouse anti-ﬂag (MBL), mouse
anti-HA (MBL) or 2-μg rabbit anti-IRF9 (Santa Cruz) and 25-μl
protein A/G-agarose (Beyotime, China) overnight at 4 1C. The
Sepharose beads were then washed three times with 1-ml lysis
buffer. The precipitates were subjected to 10% SDS-PAGE and
subsequent immunoblot analysis using the indicated antibodies.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using a ChIP assay kit (Millipore,
Billerica, MA, USA) according to the manufacturer's instructions.
Approximately 5107 HEK-293T cells were transfected with the
PBoV NP1 protein expression plasmid or the empty vector plasmid
for use in each assay. For determination of the ISRE element in the
ISG56 promoter, cells were treated with IFN-α for 6 h. Cell extracts
were then prepared, and chromatin was sonicated 10 times (30 s
at 30% of the maximum setting each time). After sonication,
protein–DNA complexes were then immunoprecipitated from
nuclear extracts using a rabbit polyclonal IRF9 antibody (Santa
Cruz), normal rabbit IgG or anti-polymerase II or mouse IgG,
followed by capture on protein A/G Sepharose beads. After IP
and elution, the DNA was ampliﬁed by real-time PCR. The results
are expressed as a signal ratio, which represents the signal to
background (IgG) ratio. The sequences of the primers used for
ampliﬁcation of ISG56 promoter are as follows: pISG56-F: 50-
CTGGCCAGTCATTGGGTTTC-30; pISG56-R: 50-GAGCTAAACAGCAGC-
CAATGG-30.
Indirect immunoﬂuorescence
HeLa cells were seeded onto microscope coverslips (NEST Co.
801007) and placed into 24-well dishes. At approximately 70% to 80%
conﬂuence, the cells were transfected with the PBoV NP1 protein
expression plasmid. After transfection for 28 h, cells were mock-
treated or treated with recombinant human IFN-α (1000 U/ml) for
30 min for detection of STAT1 or STAT2. The cells were then ﬁxed
with 4% paraformaldehyde for 15 min and permeabilized with 0.1%
Triton X-100 for 15 min at room temperature. After three washes
with PBS, the cells were blocked with PBS containing 5% goat serum
(Sigma Co. G6767) for 1 h. The cells were incubated separately with
rabbit polyclonal antibodies directed against STAT1 (1:200 Santa
Cruz) or STAT2 (1:200 Santa Cruz) and a mouse monoclonal antibody
directed against the HA tag (1:200 MBL) for 1 h at room temperature.
The cells were then treated with FITC-labeled goat anti-mouse
(1:500 Beyotime) or Alexa 594-conjugated goat anti-rabbit IgG
(1:1000 Santa Cruz) for 1 h and then stained with DAPI for 15 min
at room temperature. After three washes, images were obtained
using an Olympus Fluoview ver. 3.1 confocal laser scanning
microscope.
Statistical analysis
Data are presented as mean7standard deviations (SD). P-
values o0.05 were considered signiﬁcant, and P-values o0.01
were considered highly signiﬁcant.
Conclusion
Here, we identiﬁed PBoV NP1 protein as an antagonist of
interferon signaling and demonstrated that PBoV NP1 antagonizes
type I IFN signaling by targeting the IRF9 DNA-binding domain to
inhibit the DNA-binding activity of ISGF3. This is an efﬁcient
mechanism for viral protein to antagonize IFN signaling, providing
a possible explanation of innate immune suppression for the
pathogenesis of PBoV co-infection.
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Table 1
Primers used for plasmid constructs.
symbol Forward primer Reverse primer
NS1 ccgctcgagatggctctacttcacttcaag ccggaattcttacttacgtccgtcgtccc
NP1 ccgctcgagatgagtgggcatcacagccac ccggaattcttattttccagcttcagcttc
VP1 ccgctcgagatgaatcaattgtttcctgtg ccggaattcttacaacacttggttgattc
VP2 ccgctcgagatgtccgcacaggggggcg ccggaattcttacaacacttggttgattc
IRF-3-1-197 ccggaattcatgggaaccccaaagccacggat ccgctcgagttacaccaacagccgcttcag
IRF-9 ccggaattcatggcatcaggcagggcac ccctcgagctacaccagggacagaatgg
IRF-9-1-199 ccggaattcatggcatcaggcagggcac ggctcgagttaggcctcagttgtgtctgtaactt
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